Date: Jun 07, 2013 Author: Ayesha Khan Source: Bio News (
click here to go to the source)
Texas based company EpiCypher Inc. will collaborate with Puerto Rican CDI Laboratories for the development of Monoclonal Antibodies that will be utilized in future Epigenetics Research.
Woodlands, Texas-based EpiCypher, Inc. and CDI Laboratories (Mayaguez, Puerto Rico) have recently signed an agreement that will enable the two companies to extend collaboration in the field of research and development of monoclonal antibodies. Epigenetics is an emerging field that deals with the study of stable cellular and physiological changes that does not affect the genetic identity and nuclear characteristics of the cell.
As part of the agreement, EpiCypher's patented EpiGold™ Histone Peptide Arrays and CDI's Fast-MAb® monoclonal antibody development technology will be combined to develop novel antibodies that can work against histone modifications. Researchers believe that the modifications of histones play an important role in the epigenetic phenomena, and development of histone antibodies can be used as an effective tool in research.
The two companies are extremely excited about this new collaboration, and are expecting significant developments in the epigenetics and chromatin biology research fields. EpiCypher president Jim Bone commented:
"CDI has a terrific setup to develop monoclonal antibodies. Their Fast-MAb® system is a perfect fit with our EpiGold™ Histone Peptide Arrays"
Scott Paschke, CDI vice president and head of business development, commented on this joint venture in these words:
"EpiCypher's histone peptide array platform allows us to identify antibodies specific for histone modifications quickly and easily. We are looking forward to a lot of great histone antibodies this year."
About EpiCypher:
Texas based EpiCypher, Inc.'s renowned chromatin biology researchers provide innovative epigenetic tools and services for the development of chromatin biology research. The patented EpiGold™ Histone Peptide Array is, according to the company, the most advanced histone array available to researchers. EpiCypher Inc. is also involved in selling recombinant histone binding proteins, antibodies, nucleosomes and peptides, along with the delivery of peptide synthetic products and peptide array screening services.
